poisar

Stocks · News reference

Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva

Aug 19, 2026, 6:02 PMBenzinga Newsdesk

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

REGN
Source
benzinga
Observed
Aug 19, 2026, 6:02 PM
Checked
Aug 19, 2026, 6:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 21, 2026, 11:02 AMAndy Gould

    IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

    The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

    Read original at the-motley-fool
    AMGNVRTXREGN